Severe SARS‐CoV‐2 patients develop a higher specific T‐cell response - Université de Lille Accéder directement au contenu
Article Dans Une Revue Clinical and Translational Immunology Année : 2020

Severe SARS‐CoV‐2 patients develop a higher specific T‐cell response

Vincent Elsermans


Objectives : Assessment of the adaptive immune response against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is crucial for studying long-term immunity and vaccine strategies. We quantified IFNγ-secreting T cells reactive against the main viral SARS-CoV-2 antigens using a standardised enzyme-linked immunospot assay (ELISpot). Methods : Overlapping peptide pools built from the sequences of M, N and S viral proteins and a mix (MNS) were used as antigens. Using IFNγ T-CoV-Spot assay, we assessed T-cell and antibody responses in mild, moderate and severe SARS-CoV-2 patients and in control samples collected before the outbreak. Results : Specific T cells were assessed in 60 consecutive patients (mild, n = 26; moderate, n = 10; and severe patients, n = 24) during their follow-up (median time from symptom onset [interquartile range]: 36 days [28;53]). T cells against M, N and S peptide pools were detected in n = 60 (100%), n = 56 (93.3%), n = 55 patients (91.7%), respectively. Using the MNS mix, IFNγ T-CoV-Spot assay showed a specificity of 96.7% (95% CI, 88.5–99.6%) and a specificity of 90.3% (75.2–98.0%). The frequency of reactive T cells observed with M, S and MNS mix pools correlated with severity and with levels of anti-S1 and anti-RBD serum antibodies. Conclusion : IFNγ T-CoV-Spot assay is a reliable method to explore specific T cells in large cohorts of patients. This test may become a useful tool to assess the long-lived memory T-cell response after vaccination. Our study demonstrates that SARS-CoV-2 patients developing a severe disease achieve a higher adaptive immune response.

Mots clés

Fichier principal
Vignette du fichier
cti2.1217.pdf (1.1 Mo) Télécharger le fichier
Origine Fichiers éditeurs autorisés sur une archive ouverte

Dates et versions

hal-03288894 , version 1 (16-07-2021)




Julie Demaret, Guillaume Lefevre, Fanny Vuotto, Jacques Trauet, Alain Duhamel, et al.. Severe SARS‐CoV‐2 patients develop a higher specific T‐cell response. Clinical and Translational Immunology, 2020, 9 (12), pp.e1217. ⟨10.1002/cti2.1217⟩. ⟨hal-03288894⟩
91 Consultations
94 Téléchargements



Gmail Mastodon Facebook X LinkedIn More